200 mg-m2 melphalan – the gold standard for multiple myeloma

Palumbo and co-authors report on the results of a randomised trial comparing two doses of melphalan in patients with symptomatic multiple myeloma. Overall complete response rates, median progression-free survival and projected five-year overall survival were significantly higher among patients receiving the higher melphalan dose. These results confirm that for this patient population melphalan 200 mg/m2 should remain the gold standard conditioning regimen.

Download full article